In sal­vage ef­fort, Sel­l­as cher­ry picks some pos­i­tive mid-stage can­cer vac­cine da­ta

Eight months af­ter Sel­l­as $SLS re­verse merged its way on­to Nas­daq through what was left of Gale­na fol­low­ing the piv­otal im­plo­sion of Neu­Vax, the mi­cro­cap biotech has cher­ry picked its way through some Phase IIb da­ta to high­light ev­i­dence of the can­cer vac­cine’s pos­si­ble po­ten­tial.

Through a spokesper­son, Sel­l­as’ CEO An­ge­los Ster­giou re­fused to tell me what the p val­ue of the pri­ma­ry end­point in its study was, pre­fer­ring to high­light a clin­i­cal ben­e­fit for Neu­Vax in pro­long­ing dis­ease-free sur­vival when com­bined with Her­ceptin in treat­ing a group of breast can­cer pa­tients with triple-neg­a­tive breast can­cer. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER